Literature DB >> 30214616

Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.

Mayuko Ohuchi1, Yasuo Sakamoto1, Ryuma Tokunaga1, Yuki Kiyozumi1, Kenichi Nakamura1, Daisuke Izumi1, Keisuke Kosumi1, Kazuto Harada1, Junji Kurashige1, Masaaki Iwatsuki1, Yoshifumi Baba1, Yuji Miyamoto1, Naoya Yoshida1, Takashi Shono2, Hideaki Naoe2, Yutaka Sasaki2, Hideo Baba1.   

Abstract

The adenoma-carcinoma sequence, the sequential mutation and deletion of various genes by which colorectal cancer progresses, is a well-established and accepted concept of colorectal cancer carcinogenesis. Proteins of the polycomb repressive complex 2 (PRC2) function as transcriptional repressors by trimethylating histone H3 at lysine 27; the activity of this complex is essential for cell proliferation and differentiation. The histone methyltransferase enhancer of zeste homolog 2 (EZH2), an essential component of PRC2, is associated with the transcriptional repression of tumor suppressor genes. EZH2 expression has previously been reported to increase with the progression of pancreatic intraductal papillary mucinous neoplasm. Thus, we hypothesized that EZH2 expression also increases during the adenoma-carcinoma sequence of colorectal cancer. The present study investigated changes in EZH2 expression during the colorectal adenoma-carcinoma sequence. A total of 47 patients with colorectal adenoma, 20 patients with carcinoma in adenoma and 43 patients with colorectal carcinoma who underwent surgical or endoscopic resection were enrolled in this study. Non-cancerous tissue from the clinical specimens was also examined. The association between EZH2 expression, pathology and expression of tumor suppressor genes during colorectal carcinogenesis were analyzed. Each specimen was immunohistochemically stained for EZH2, proliferation marker protein Ki-67 (Ki-67), cyclin-dependent kinase inhibitor (CDKN) 1A (p21), CDKN1B (p27) and CDKN2A (p16). Total RNA was extracted from formalin-fixed paraffin-embedded blocks and reverse transcription-quantitative polymerase chain reaction analysis of these genes was performed. Ki-67 and EZH2 expression scores increased significantly during the progression of normal mucosa to adenoma and carcinoma (P=0.009), and EZH2 expression score was positively associated with Ki-67 expression score (P=0.02). Conversely, p21 mRNA and protein expression decreased significantly, whereas expression of p27 and p16 did not change significantly. During the carcinogenesis sequence from normal mucosa to adenoma and carcinoma, EZH2 expression increased and p21 expression decreased significantly. EZH2 may therefore contribute to the development of colorectal cancer from adenoma via suppression of p21.

Entities:  

Keywords:  adenoma-carcinoma sequence; colorectal cancer; enhancer of zeste homolog 2; p21

Year:  2018        PMID: 30214616      PMCID: PMC6126222          DOI: 10.3892/ol.2018.9240

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes.

Authors:  Carrie S Ketel; Erica F Andersen; Marcus L Vargas; Jinkyo Suh; Susan Strome; Jeffrey A Simon
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

3.  Polycomb complexes repress developmental regulators in murine embryonic stem cells.

Authors:  Laurie A Boyer; Kathrin Plath; Julia Zeitlinger; Tobias Brambrink; Lea A Medeiros; Tong Ihn Lee; Stuart S Levine; Marius Wernig; Adriana Tajonar; Mridula K Ray; George W Bell; Arie P Otte; Miguel Vidal; David K Gifford; Richard A Young; Rudolf Jaenisch
Journal:  Nature       Date:  2006-04-19       Impact factor: 49.962

4.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

5.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.

Authors:  Outi R Saramäki; Teuvo L J Tammela; Paula M Martikainen; Robert L Vessella; Tapio Visakorpi
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

6.  Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Authors:  Hua Li; Qi Cai; Andrew K Godwin; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2010-11-29       Impact factor: 5.852

7.  EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation.

Authors:  Roland Hubaux; Kelsie L Thu; Bradley P Coe; Calum MacAulay; Stephen Lam; Wan L Lam
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

8.  EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

Authors:  Tao Fan; Shunlin Jiang; Nancy Chung; Ali Alikhan; Christina Ni; Chyi-Chia Richard Lee; Thomas J Hornyak
Journal:  Mol Cancer Res       Date:  2011-03-07       Impact factor: 5.852

9.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 10.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

View more
  10 in total

Review 1.  Polycomb repressive 2 complex-Molecular mechanisms of function.

Authors:  Valentina L Kouznetsova; Alex Tchekanov; Xiaoming Li; Xiaowen Yan; Igor F Tsigelny
Journal:  Protein Sci       Date:  2019-06-10       Impact factor: 6.725

2.  Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.

Authors:  Samar M Abdel Raouf; Taiseer R Ibrahim; Lobna A Abdelaziz; Mohamed I Farid; Salem Y Mohamed
Journal:  J Gastrointest Cancer       Date:  2021-03

Review 3.  Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation.

Authors:  Alireza Lorzadeh; Maile Romero-Wolf; Ajay Goel; Unmesh Jadhav
Journal:  Gastroenterology       Date:  2021-03-26       Impact factor: 33.883

4.  EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.

Authors:  Chen Li; Jiagui Song; Zhengyang Guo; Yueqing Gong; Tengrui Zhang; Jiaqi Huang; Rui Cheng; Xiaotong Yu; Yanfang Li; Li Chen; Xiaojuan Ma; Yan Sun; Yan Wang; Lixiang Xue
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

5.  Polycomb and Trithorax Group Proteins: The Long Road from Mutations in Drosophila to Use in Medicine.

Authors:  D A Chetverina; D V Lomaev; M M Erokhin
Journal:  Acta Naturae       Date:  2020 Oct-Dec       Impact factor: 1.845

6.  The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.

Authors:  Natsuki Saigusa; Hideaki Hirai; Yuichiro Tada; Daisuke Kawakita; Masato Nakaguro; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Takahito Kondo; Kenji Okami; Takafumi Togashi; Yukiko Sato; Makoto Urano; Manami Kajiwara; Tomotaka Shimura; Chihiro Fushimi; Akira Shimizu; Isaku Okamoto; Takuro Okada; Takayoshi Suzuki; Yorihisa Imanishi; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Yuichiro Sato; Yoshitaka Honma; Keisuke Yamazaki; Yushi Ueki; Toyoyuki Hanazawa; Yuki Saito; Hideaki Takahashi; Mizuo Ando; Shinji Kohsaka; Takashi Matsuki; Toshitaka Nagao
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

7.  Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer.

Authors:  Qian-Qian Wang; Yuan-Chen Zhou; Yu-Jia Zhou Ge; Geng Qin; Teng-Fei Yin; Dong-Yan Zhao; Chang Tan; Shu-Kun Yao
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

8.  Comprehensive RNA Sequencing in Adenoma-Cancer Transition Identified Predictive Biomarkers and Therapeutic Targets of Human CRC.

Authors:  Mingzhe Zhu; Yanqi Dang; Zhenhua Yang; Yang Liu; Li Zhang; Yangxian Xu; Wenjun Zhou; Guang Ji
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-04       Impact factor: 8.886

9.  Epithelial-Mesenchymal Transition-Related MicroRNAs and Their Target Genes in Colorectal Cancerogenesis.

Authors:  Branislava Ranković; Nina Zidar; Margareta Žlajpah; Emanuela Boštjančič
Journal:  J Clin Med       Date:  2019-10-03       Impact factor: 4.241

Review 10.  Clinicopathologic significance of protein lysine methyltransferases in cancer.

Authors:  Theodore Vougiouklakis; Benjamin J Bernard; Nupur Nigam; Kyunghee Burkitt; Yusuke Nakamura; Vassiliki Saloura
Journal:  Clin Epigenetics       Date:  2020-10-13       Impact factor: 6.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.